Description of the treatment regimen: Bortezomib: 1.3 mg/m2 as i.v. bolus injection, given
on days 1, 4, 8, and 11 of each treatment cycle; Rituximab: 375 mg/m2 infusion, day 1 of
each cycle; Dexamethasone: 40 mg per day orally (days 1 – 4) of each treatment cycle.
Treatment will be given for a total of 6 cycles (every 21 days), followed by maintenance
treatment with rituximab (375 mg/m2 every two months for 4 times)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
response rate
Johannes Drach, MD
Principal Investigator
Medical University Vienna
Austria: Federal Ministry for Health and Women
2004-002150-64
NCT00261612
January 2005
January 2007
Name | Location |
---|